Velesco Pharma to triple its clinical manufacturing capacity

4 Sep 2019

Company's new building in Wixom, MI replace and consolidate its existing manufacturing site in Kalamazoo, MI.

Velesco Pharma, is set to triple its clinical manufacturing capacity with the purchase and fit-out of a new, state-of-the-art facility in Wixom, Michigan.

Velesco Pharma to triple its clinical manufacturing capacity

The new building will feature expanded processing suite space to provide enhanced cGMP clinical trial material capabilities. This facility will be supported by Velesco Pharma’s existing QC release and stability testing laboratory also located in Wixom. It will replace and consolidate the company’s existing manufacturing site in Kalamazoo, MI.

As part of the expansion, the company has continued to invest in its growing team with the recent promotion of two senior leaders. Peter Angus has moved into the role of Vice President of Research while Lisa Crandall is now Vice President of Development. Both have been with Velesco Pharma since its inception.

Founded in 2007, Velesco Pharma supports early and later stage drug development through contract analytical and drug formulation services, along with cGMP clinical supplies offering a full range of non-sterile dosage forms.

Dave Barnes, Velesco Pharma’s CEO: “This investment in new space and increase in our capacity will enable us to meet growing client demands for cGMP clinical manufacturing services while still maintaining our science-focus and flexible approach to client projects.

“Our team forged their careers in big pharma R&D and bring a wealth of expertise to the table. This experience combined with our personalized and agile approach makes us an ideal choice for clients in the critical early and later stage drug development phases.

“As a business, we have always placed great emphasis on adding scientific value to the drug development process and this continues to be central to our ethos as we expand and move forward.”

The new facility is set to be fully operational by the end of this year.

Read More

Related news

New microbial air sampler addresses continuous monitoring

New microbial air sampler addresses continuous monitoring

14 Nov 2019

The device supports the new EU GMP Annex 1 requirements.

Read more 
GVK Bio continues to see growth tailwinds for 2020 thanks to a ‘crescendo of factors’

GVK Bio continues to see growth tailwinds for 2020 thanks to a ‘crescendo of factors’

13 Nov 2019

China-US trade challenges has led to de-risking by pharma companies.

Read more 
Winners of the 16th Pharma Awards

Winners of the 16th Pharma Awards

11 Nov 2019

Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.

Read more 
CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies

CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies

8 Nov 2019

But personalized medicines will require new logistics and manufacturing systems.

Read more 
SGH Healthcaring unveils its new asthma spacer device

SGH Healthcaring unveils its new asthma spacer device

8 Nov 2019

Zephyr's revolutionary new design improves drug administration and simplifies treatment delivery for better observance.

Read more 
Recipharm expands Indian injectable dosage form capabilities

Recipharm expands Indian injectable dosage form capabilities

7 Nov 2019

Partnership will combine capabilities and expertise in Europe and India to build a new facility dedicated to injectable formulations to supply demand from Europe and overseas territories.

Read more 
Aptar acquires a leader in drug delivery training devices and patient onboarding

Aptar acquires a leader in drug delivery training devices and patient onboarding

6 Nov 2019

Acquisition reflects movement of treatments being administered by patients at home rather than by healthcare providers.

Read more 
Europe predicted to surpass the US in biologic manufacturing capacity by 2023

Europe predicted to surpass the US in biologic manufacturing capacity by 2023

6 Nov 2019

Demand for biological manufacturing is growing faster than capacity growth.

Read more 
SP acquires Spain based global provider of complete sterile filling lines

SP acquires Spain based global provider of complete sterile filling lines

5 Nov 2019

Company's strategic move reflects its expectation of short-run aseptic liquid filling to continue to drive pharmaceutical growth.

Read more 
Legacy recruits heavily to meet growing steriles demand

Legacy recruits heavily to meet growing steriles demand

5 Nov 2019

Company to reach 250 employees by year end to meet growing drug product manufacturing demand.

Read more